These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9871434)

  • 21. Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion.
    Porter RH; Greene JG; Higgins DS; Greenamyre JT
    J Neurosci; 1994 Nov; 14(11 Pt 2):7192-9. PubMed ID: 7965108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease.
    Amalric M
    Curr Opin Pharmacol; 2015 Feb; 20():29-34. PubMed ID: 25462289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Involvement of basal ganglia transmitter systems in movement initiation.
    Hauber W
    Prog Neurobiol; 1998 Dec; 56(5):507-40. PubMed ID: 9775402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional anatomy of thalamus and basal ganglia.
    Herrero MT; Barcia C; Navarro JM
    Childs Nerv Syst; 2002 Aug; 18(8):386-404. PubMed ID: 12192499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains.
    Smith Y; Villalba R
    Mov Disord; 2008; 23 Suppl 3():S534-47. PubMed ID: 18781680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Shifts in striatal responsivity evoked by chronic stimulation of dopamine and glutamate systems.
    Canales JJ; Capper-Loup C; Hu D; Choe ES; Upadhyay U; Graybiel AM
    Brain; 2002 Oct; 125(Pt 10):2353-63. PubMed ID: 12244091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional Relevance of Different Basal Ganglia Pathways Investigated in a Spiking Model with Reward Dependent Plasticity.
    Berthet P; Lindahl M; Tully PJ; Hellgren-Kotaleski J; Lansner A
    Front Neural Circuits; 2016; 10():53. PubMed ID: 27493625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release.
    Sakellaridis NE
    Neurosurgery; 2005 Mar; 56(3):E629; author reply E629. PubMed ID: 18235260
    [No Abstract]   [Full Text] [Related]  

  • 29. The distribution of excitatory amino acid receptors in the normal human midbrain and basal ganglia with implications for Parkinson's disease: a quantitative autoradiographic study using [3H]MK-801, [3H]glycine, [3H]CNQX and [3H]kainate.
    Ball EF; Shaw PJ; Ince PG; Johnson M
    Brain Res; 1994 Sep; 658(1-2):209-18. PubMed ID: 7834343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia.
    Klockgether T; Turski L
    Ann Neurol; 1993 Oct; 34(4):585-93. PubMed ID: 7692810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrating neurotransmission in striatal medium spiny neurons.
    Girault JA
    Adv Exp Med Biol; 2012; 970():407-29. PubMed ID: 22351066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glutamate-dopamine-GABA interactions in the aging basal ganglia.
    Mora F; Segovia G; Del Arco A
    Brain Res Rev; 2008 Aug; 58(2):340-53. PubMed ID: 18036669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia.
    Vila M; Marin C; Ruberg M; Jimenez A; Raisman-Vozari R; Agid Y; Tolosa E; Hirsch EC
    J Neurochem; 1999 Jul; 73(1):344-52. PubMed ID: 10386987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frontal-striatal circuit functions: context, sequence, and consequence.
    Saint-Cyr JA
    J Int Neuropsychol Soc; 2003 Jan; 9(1):103-27. PubMed ID: 12570364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The endocannabinoid system in Parkinson's disease.
    Di Filippo M; Picconi B; Tozzi A; Ghiglieri V; Rossi A; Calabresi P
    Curr Pharm Des; 2008; 14(23):2337-47. PubMed ID: 18781984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reciprocal dopamine-glutamate modulation of release in the basal ganglia.
    Morari M; Marti M; Sbrenna S; Fuxe K; Bianchi C; Beani L
    Neurochem Int; 1998 Nov; 33(5):383-97. PubMed ID: 9874089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.
    Di Matteo V; Pierucci M; Esposito E; Crescimanno G; Benigno A; Di Giovanni G
    Prog Brain Res; 2008; 172():423-63. PubMed ID: 18772045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GluR1 glutamate receptor subunit is regulated differentially in the primate basal ganglia following nigrostriatal dopamine denervation.
    Betarbet R; Porter RH; Greenamyre JT
    J Neurochem; 2000 Mar; 74(3):1166-74. PubMed ID: 10693949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The biochemistry of the basal ganglia and Parkinson's disease.
    Curzon G
    Postgrad Med J; 1977 Dec; 53(626):719-25. PubMed ID: 24209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease.
    Blandini F; Nappi G; Greenamyre JT
    Ann Neurol; 2001 Apr; 49(4):525-9. PubMed ID: 11310632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.